DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: While not specifically optimized for detecting exon‐level DMD deletions and duplications, chromosomal microarray (CMA) has the ability to detect many DMD copy number changes, even though it is a broad first‐tier test to assess for copy number changes responsible for developmental disabilities or congenital anomalies (Miller et al., 2010), and is not specifically indicated to evaluate for dystrophinopathies.